The Japanese Ministry of Health, Labour and Welfare (MHLW) has granted approval for the use of GSK’s Blenrep (belantamab ...

The revitalisation of GSK's blood cancer therapy Blenrep has continued with a second regulatory approval, in Japan, as a ...

Japan’s Ministry of Health, Labor and Welfare (MHLW) has approved UK pharma major GSK’s (LSE: GSK) Blenrep (belantamab ...

GSK plc has received approval for Blenrep combinations from Japan's Ministry of Health, Labour and Welfare (MHLW) for the ...

GSK’s Blenrep combinations receives Japanese approval for treatment of relapsed/refractory multiple myeloma: London, UK Tuesday, May 20, 2025, 12:00 Hrs [IST] GSK plc announced ...

Managed Healthcare Executive gives C-suite executives in health plans and provider organizations news and strategies for ...

The pharma company said it expects more approvals through the year following positive results from a Phase 3 trial.

(Alliance News) - GSK PLC on Monday said it has received approval in Japan for Blenrep combinations in the treatment of adults with relapsed or refractory multiple myeloma.

Investing.com -- GSK plc (LON: GSK ), a U.K.-based pharmaceutical company, said on Monday that its Blenrep combinations have been approved by Japan’s Ministry of Health. This approval is for the ...

The tolerability and safety profiles of the Blenrep combos align with those of the individual agents involved. Its combos are being reviewed in 14 nations, including the US, Japan, the European ...

GSK has received approval from Japan’s Ministry of Health, Labour and Welfare (MHLW) for Blenrep combinations to treat adults with relapsed or ...

GSK's Blenrep treatment has been approved by Japanese regulators when in combination for relapsed or refractory multiple myeloma, marking the second major approval of its kind for the drug, with more ...